Clinical trial • Phase I • Immunology
OBE-CEL for Refractory progressive multiple sclerosis | Progressive multiple sclerosis
Phase I trial of OBE-CEL for Refractory progressive multiple sclerosis | Progressive multiple sclerosis. open-label. 15 participants.
Overview
- Trial Therapeutic Area
- Immunology
- Trial Disease
- Refractory progressive multiple sclerosis | Progressive multiple sclerosis
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 14-04-2025
- First CTIS Authorization Date
- 26-06-2025
Trial design
open-label Phase I trial across 2 sites in Spain.
- Open Label
- Yes
- Target Sample Size
- 15
Recruitment
- Planned Sample Size
- 15
- Recruitment Window Months
- 39
Geography
- Total Number Of Sites
- 2
- Total Number Of Participants
- 15
Spain
- Earliest CTIS Part Ii Submission Date
- 19-05-2025
- Latest Decision Or Authorization Date
- 22-09-2025
- Processing Time Days
- 126
- Number Of Sites
- 2
- Number Of Participants
- 3
Sites
- Site Name
- Hospital Universitari Vall D Hebron
- Department Name
- Neurology
- Contact Person Name
- Xavier Montalban
- Contact Person Email
- ctrials@cem-cat.org
- Site Name
- Hospital Universitario Y Politecnico La Fe
- Department Name
- Neurology
- Contact Person Name
- Francisco Perez Miralles
- Contact Person Email
- miralles_neuro@hotmail.com
Sponsor
Primary sponsor
- Full Name
- Autolus Limited
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United Kingdom
Investigational products
- Investigational Product Name
- OBE-CEL
Related trials
Other published trials that may interest you.
- BELIMUMAB for Antibody-mediated rejection (kidney transplant)|High HLA sensitization (transplant candidates)
- Belimumab for Systemic lupus erythematosus
- INEBILIZUMAB for Myasthenia gravis
- PREDNISONE for Granulomatosis with polyangiitis (Wegener's) | Microscopic polyangiitis | ANCA-associated vasculitis
- BIRCH POLLEN ALLERGOID GLUTARALDEHYDE MODIFIED for Allergic rhinitis due to birch pollen | Allergic rhinoconjunctivitis